Search

Drug–target–drug complexes (DTDCs) are phenomena newly observed in patients who switch from the complement component 5 (C5) inhibitor eculizumab to crovalimab, a novel, anti-C5 antibody in development for paroxysmal nocturnal hemoglobinuria (PNH), because these agents bind to different C5 epitopes. In Part 3 of the four-part, phase I/II COMPOSER study, 19 patients with PNH switching from eculizumab received 1,000-mg crovalimab intravenously, then subcutaneous maintenance doses from Day 8 (680 mg every 4 weeks (q4w), 340 mg every 2 weeks, or 170 mg every week). Crovalimab exposure was transiently reduced, and size-exclusion chromatography and crovalimab-specific enzyme-linked immunosorbent assays revealed DTDCs in all 19 patients' sera. Additionally, self-limiting mild to moderate symptoms suggestive of type III hypersensitivity reactions occurred in two patients. Mathematical modeling simulations of DTDC kinetics and effects of dosing on DTDC size distribution using Part 3 data predicted that increased crovalimab concentrations could reduce the proportion of large, slow-clearing DTDCs in the blood. A simulation-guided, optimized crovalimab regimen (1,000 mg intravenously; four weekly, subcutaneous 340-mg doses; then 680 mg q4w from Day 29) was evaluated in Part 4. Confirming the model's predictions, mean proportions of large DTDCs in patients who switched from eculizumab to this optimized regimen decreased by > 50% by Day 22, and target crovalimab concentrations were maintained. No type III hypersensitivity reactions occurred in Part 4. Optimizing crovalimab dosing thus reduced the proportion of large DTDCs, ensured adequate complement inhibition, and may improve safety. Model-based dosing optimization to mitigate DTDC formation offers a useful strategy for patients switching to novel antibody treatments targeting soluble epitopes.

Free-standing and flexible air electrodes with long-lasting bifunctional activities for both the oxygen reduction reaction (ORR) and the oxygen evolution reaction (OER) are crucial to the development of wearable Zn-air rechargeable batteries. In this work, we synthesize a flexible air electrode consisting of 3D nanoporous N-doped graphene with trimodal shells and Ni particles through repeated chemical vapor deposition (CVD) and acidic etching processes. Our results indicate that such trimodal graphene morphology significantly enhances the active N-dopant sites and graphene-coated Ni surface, which consequentially boosts both the ORR and OER activities, as well as catalytic durability. First-principles density functional theory (DFT) calculations reveal the synergetic effects between the Ni and the N-doped graphene; namely, the Ni nanoparticles boost the bifunctional activities of the coated N-doped graphene, and in turn the graphene-covering layers enhance the stability of Ni. Thanks to the better protection from the triple graphene shells, our trimodal N-doped graphene/Ni-based Zn-air battery can be stably discharged/recharged beyond 2500 h with low overpotentials. It is reasonable to expect that such free-standing trimodal graphene/Ni would be promising in many flexible energy conversion/storage devices.

Supplementary Figures 1-2 from Oncolytic Herpes Simplex Virus Vector G47Δ in Combination with Androgen Ablation for the Treatment of Human Prostate Adenocarcinoma

Supplementary Figure 2 from Oncolytic Herpes Simplex Virus Vector G47Δ in Combination with Androgen Ablation for the Treatment of Human Prostate Adenocarcinoma

Supplementary Methods from Oncolytic Herpes Simplex Virus Vector G47Δ in Combination with Androgen Ablation for the Treatment of Human Prostate Adenocarcinoma

Supplementary Figure 1 from Oncolytic Herpes Simplex Virus Vector G47Δ in Combination with Androgen Ablation for the Treatment of Human Prostate Adenocarcinoma

Developing cheap and highly durable non-noble metal catalysts for water electrolysis to sustainably produce hydrogen as alternatives to platinum-based catalysts is essential. Herein, we report graphene-encapsulated NiMo alloys as acid-stable non-noble metal catalyst electrodes. The graphene-encapsulated NiMo cathode showed a highly stable performance in the potential cycling test (10,000 cycles) from 0 to 5.0 A cm−2 and 100 h of durability at a 2.2 V constant cell voltage. A balance between catalytic activity and corrosion in acidic environments was achieved by tuning the number of N-doped graphene layers. Through their application in a full-cell PEM-type water electrolyzer, we verify that noble metal catalysts can be replaced by non-noble metal catalysts. Such cheap acid-stable non-noble metal electrodes have promising practical applications in PEM-type water electrolysis.

Electron doping of graphene has been extensively studied on graphene-supported surfaces, where the metallicity is influenced by the substrate. Herewith we propose potassium adsorption on free-standing nanoporous graphene, thus eluding any effect due to the substrate. We monitor the electron migration in the π* downward-shifted conduction band. In this rigid band shift, we correlate the spectral density of the π* state in the upper Dirac cone with the associated plasmon, blue-shifted with increasing K dose, as deduced by electron energy loss spectroscopy. These results are confirmed by the Dirac plasmon activated by the C 1s emitted electrons, thanks to spatially resolved photoemission. This crosscheck constitutes a reference on the correlation between the electronic π* states in the conduction band and the Dirac plasmon evolution upon in situ electron doping of fully free-standing graphene.

The application scope of metal-organic frameworks (MOFs) can be extended by rationally designing the architecture and components of MOFs, which can be achieved via a metal-containing solid templated strategy. However, this strategy suffers from low efficiency and provides only one specific MOF from one template. Herein, we present a versatile templated strategy in which organic ligands are weaved into hydrogen-bonded organic frameworks (HOFs) for the controllable and scalable synthesis of MOF nanotubes. HOF nanowires assembled from benzene-1,3,5-tricarboxylic acid and melamine via a simple sonochemical approach serve as both the template and precursor to produce MOF nanotubes with varied metal compositions. Hybrid nanotubes containing nanometal crystals and N-doped graphene prepared through a carbonization process show that the optimized NiRuIr alloy@NG nanotube exhibits excellent electrocatalytic HER activity and durability in alkaline media, outperforming most reported catalysts. The strategy proposed here demonstrates a pioneering study of combination of HOF and MOF, which shows great potential in the design of other nanosized MOFs with various architectures and compositions for potential applications.

Geometric structures of carbon networks are key in designing their material properties. In particular, optimization of curved structures through the introduction of topological defects and doping of heteroatoms in the lattice is crucial to the design of carbon-based, non-noble-metal-free catalysts. A simple and practical mathematical model based on discrete geometric analysis is proposed to describe the geometric features of carbon networks and their relationships to their material properties. This model can pre-screen candidates for novel material design, and these candidates can be further examined by the density functional theory (DFT). Inspired by observations regarding the preferential doping of heteroatoms at local curved sites, the important characteristics of the candidate material were experimentally realized, and its enhanced catalytic activity facilitated by chemical dopants was confirmed in the designed carbon network.

Nitrogen (N) doping is one of the most effective approaches to tailor the chemical and physical properties of graphene. By the interplay between N dopants and 3D curvature of graphene lattices, N-doped 3D graphene displays superior performance in electrocatalysis and solar-energy harvesting for energy and environmental applications. However, the electrical transport properties and the electronic states, which are the key factors to understand the origins of the N-doping effect in 3D graphene, are still missing. The electronic properties of N-doped 3D graphene are systematically investigated by an electric-double-layer transistor method. It is demonstrated that Urbach-tail-like localized states are located around the neutral point of N-doped 3D graphene with the background metallic transport channels. The dual nature of electronic states, generated by the synergistic effect of N dopants and 3D curvature of graphene, can be the electronic origin of the high electrocatalysis, enhanced molecular adsorption, and light absorption of N-doped 3D graphene.

Electrochemical CO2 reduction is a key technology to recycle CO2 as a renewable resource, but adsorbing CO2 on the catalyst surface is challenging. We explored the effects of reduced graphene oxide...

In this paper, we report the direct visualization of heat trapping in the pores of a three-dimensional bi-continuous nanoporous graphene film and its application to a self-standing, bendable broadband terahertz (THz) and infrared (IR) detector. Utilizing a scattering-type scanning near-field optical microscope in the mid-IR region, we directly visualized that IR-induced heat is localized in the vicinities of the material nanopores. Nanoscale images of the IR amplitudes also revealed that this heat localization effect became stronger with decreasing pore diameter, and this behavior is consistent with the pore-size dependence of the global thermal conductivity and light reflection. We also found that this material exhibits a high THz and IR absorption rate (>99%), while retaining the Dirac properties of single-layer graphene; on the other hand, conventional graphene loses such properties with increasing number of layers. These unique features enabled us to develop a highly sensitive, bendable THz and IR detector with low thermal conductivity due to heat localization in the vicinities of the nanopores, bendability, and high thermopower using a p-n junction. Thus, through controlled heat conduction by the appropriate design of pore structures, this nanoporous graphene could be applied in wearable thermal devices of broadband energy harvesters and detectors.

High-entropy alloys (HEAs) are near-equimolar alloys comprising five or more elements. In recent years, catalysis using HEAs has attracted considerable attention across various fields. Herein, we demonstrate the facile synthesis of nanoporous ultra-high-entropy alloys (np-UHEAs) with hierarchical porosity via dealloying. These np-UHEAs contain up to 14 elements, namely, Al, Ag, Au, Co, Cu, Fe, Ir, Mo, Ni, Pd, Pt, Rh, Ru, and Ti. Furthermore, they exhibit high catalytic activities and electrochemical stabilities in the hydrogen evolution reaction (HER) and oxygen evolution reaction (OER) in acidic media, superior to that of commercial Pt/graphene and IrO2 catalysts. Our results offer valuable insights for the selection of elements as catalysts for various applications., Nanoporous ultra-high-entropy alloys containing 14 elements (Al, Ag, Au, Co, Cu, Fe, Ir, Mo, Ni, Pd, Pt, Rh, Ru, and Ti) were obtained by dealloying. The products showed excellent electrocatalytic performance for water splitting in acidic media.

Identifying the influence of the phase of a catalyst on its reactivity is crucial for guiding the rational design of highly active electrocatalysts. Herein, we unveil the phase-dependent reactivity...

Protecting alkali metals from oxygen crossover is a key unsolved challenge in metal–oxygen batteries. Herein, we report a new “reactive-armor strategy” by using freestanding three-dimensional sulfu...

Complement C5 inhibition is the standard of care (SoC) for patients with paroxysmal nocturnal hemoglobinuria (PNH) with significant clinical symptoms. Constant and complete suppression of the terminal complement pathway and the high serum concentration of C5 pose challenges to drug development that result in IV-only treatment options. Crovalimab, a sequential monoclonal antibody recycling technology antibody was engineered for extended self-administered subcutaneous dosing of small volumes in diseases amenable for C5 inhibition. A 3-part open-label adaptive phase 1/2 trial was conducted to assess safety, pharmacokinetics, pharmacodynamics, and exploratory efficacy in healthy volunteers (part 1), as well as in complement blockade–naive (part 2) and C5 inhibitor–treated (part 3) PNH patients. Twenty-nine patients were included in part 2 (n = 10) and part 3 (n = 19). Crovalimab concentrations exceeded the prespecified 100-µg/mL level and resulted in complete and sustained terminal complement pathway inhibition in treatment-naive and C5 inhibitor–pretreated PNH patients. Hemolytic activity and free C5 levels were suppressed below clinically relevant thresholds (liposome assay

Understanding the formation and evolution of bicontinuous nanoporous structure during dealloying has been one of the most challenging subjects of dealloying research. However, previous in situ investigations either suffer from insufficient spatial resolution (e.g., X-ray tomography) or lack morphology visualization and mass information (e.g., scanning tunneling microscopy). In this work, we report the kinetics of the whole course of dealloying by utilizing liquid-cell aberration-corrected scanning transmission electron microscopy. With Z-contrast imaging analysis, the in situ sub-nanoscale characterization reveals two new phenomena, an initial period of dealloying indicative of an initial length scale for bulk dealloying and a large volume shrinkage in a nanoscale alloy precursor. We explain the particle-size-dependent volume shrinkage with the formation of a dense shell and quantify the dependence with a simple geometric model. These insights into the mechanisms of dealloying will enable deliberate designs of nanoporous structures.

The hypomethylating agent azacitidine (AZA) significantly extends overall survival (OS) in patients with higher risk myelodysplastic syndromes (MDS), when compared with other conventional care regimens, including supportive care and low-dose and intensive chemotherapy. However, the effects of 5- and 7-day treatment schedules of AZA (AZA-5 and AZA-7, respectively) on the OS of MDS patients had not been compared prospectively. We started a phase 3 trial comparing the effects of AZA-7 and AZA-5 on MDS patients with refractory anemia with excess blasts (RAEB) and RAEB in transformation (RAEB-T). However, this trial was prematurely terminated because of poor recruitment. Using all data, there was no significant difference in the OS of patients between AZA-7 (92 patients) and AZA-5 (95 patients), with the 2-year OS rates of AZA-7 and AZA-5 at 36.4% and 25.8%, respectively (P = 0.293). Adverse event profiles were similar between the two groups. Interestingly, data of the centrally diagnosed RAEB and RAEB-T cases showed that AZA-7 significantly prolonged the time to leukemia transformation compared with AZA-5 (P = 0.022), confirmed by multivariate analysis. Although this trial could not provide definite evidence, the results support the use of AZA-7 for RAEB and RAEB-T. (UMIN Clinical Trials Registry UMIN000009633).

A multicenter phase II study was conducted in 44 elderly (≥ 65 years) Japanese patients with newly diagnosed acute myeloid leukemia (AML) to evaluate whether azacitidine is also effective and feasible in Japanese AML patients. The 28 patients with AML with poor-risk cytogenetics and/or myelodysplasia-related changes (unfavorable AML) were randomly assigned to receive either azacitidine or conventional care regimens (CCR), and the other 16 patients without unfavorable AML received azacitidine alone. The primary endpoint was overall survival. At the median follow-up of 29 months, among the 26 evaluable patients with unfavorable AML, the median survival time (MST) of patients who received azacitidine (N = 14) was 9.6 months and that of patients who received CCR (N = 12) was 5.3 months (HR 0.73; 95% CI 0.31-1.69; log-rank P = 0.459). The MST of all 29 patients who received azacytidine, including the 15 evaluable patients without unfavorable AML, was 12.4 months. Adverse events of azacitidine were manageable and consistent with its established safety profile. Azacitidine tended to prolong survival in newly diagnosed elderly Japanese patients with AML, and was feasible as a front-line therapy for elderly AML patients.